Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy

Br J Haematol. 2013 Mar;160(6):861-3. doi: 10.1111/bjh.12178. Epub 2012 Dec 24.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cohort Studies
  • Cytarabine / administration & dosage
  • Disease-Free Survival
  • Female
  • Humans
  • Induction Chemotherapy
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / pathology*
  • Male
  • Middle Aged
  • Remission Induction
  • Risk Factors
  • Survival Analysis
  • Treatment Outcome
  • Young Adult

Substances

  • Cytarabine